

116TH CONGRESS
1ST SESSION

S. _____

To amend titles XVIII and XIX of the Social Security Act to provide equal coverage of in vitro specific IgE tests and percutaneous tests for allergies under the Medicare and Medicaid programs, and for other purposes.

IN THE SENATE OF THE UNITED STATES

Mr. MORAN introduced the following bill; which was read twice and referred to the Committee on _____

A BILL

To amend titles XVIII and XIX of the Social Security Act to provide equal coverage of in vitro specific IgE tests and percutaneous tests for allergies under the Medicare and Medicaid programs, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Allergy Testing Access
5 Act of 2019”.

6 **SEC. 2. FINDINGS.**

7 Congress finds the following:

1 (1) Allergies, when not properly diagnosed, can-
2 not be effectively treated.

3 (2) Allergies to food, inhaled particles, or other
4 sources can cause debilitating and, in some cases,
5 fatal reactions.

6 (3) Allergies can substantially compound other
7 illnesses, including asthma, emphysema, and adult
8 obstructive pulmonary diseases, leading to social and
9 economic costs for families and our Nation's health
10 care system.

11 (4) According to clinical guidelines from the
12 National Institutes of Health and recommendations
13 from peer-reviewed literature, in vitro specific IgE
14 tests and percutaneous tests are considered equiva-
15 lent as confirmatory tests in terms of their sensi-
16 tivity and accuracy.

17 (5) Despite these recommendations, some cur-
18 rent Medicare local coverage determinations and
19 Medicaid coverage policies deny equal access to in
20 vitro specific IgE tests and percutaneous tests.

21 (6) In vitro specific IgE tests and percutaneous
22 tests must be equally accessible for clinicians and
23 patients to improve health outcomes, reduce system
24 costs, and reduce current health care disparities
25 caused by the lack of equal coverage.

1 **SEC. 3. MEDICAID COVERAGE FOR ALLERGY DIAGNOSTIC**
2 **TESTING SERVICES.**

3 (a) IN GENERAL.—Title XIX of the Social Security
4 Act (42 U.S.C. 1396 et seq.) is amended—

5 (1) in section 1902(a)—

6 (A) in paragraph (85), by striking “and”
7 at the end;

8 (B) in paragraph (86), by striking the pe-
9 riod at the end and inserting “; and”; and

10 (C) by inserting after paragraph (86) the
11 following new paragraph:

12 “(87) provide, with respect to the provision of
13 allergy diagnostic testing services (as defined in sec-
14 tion 1905(ff)) under the State plan, for equality in
15 the treatment of in vitro specific IgE tests and
16 percutaneous tests with respect to—

17 “(A) any medical necessity or other cov-
18 erage requirements established for such in vitro
19 specific IgE and percutaneous tests;

20 “(B) any frequency limits established for
21 such tests; and

22 “(C) any allergen unit limits established
23 for such tests.”; and

24 (2) in section 1905—

25 (A) in subsection (r)—

1 (i) by redesignating paragraph (5) as
2 paragraph (6); and

3 (ii) by inserting after paragraph (4)
4 the following new paragraph:

5 “(5) Allergy diagnostic testing services (as de-
6 fined in subsection (ff)).”; and

7 (B) by adding at the end the following new
8 subsection:

9 “(ff) ALLERGY DIAGNOSTIC TESTING SERVICES DE-
10 FINED.—The term ‘allergy diagnostic testing services’
11 means in vitro specific IgE tests and percutaneous tests
12 that—

13 “(1) have been cleared under section 501(k),
14 classified under section 513(f)(2), or approved under
15 section 515 of the Federal Food, Drug, and Cos-
16 metic Act; and

17 “(2) are provided to individuals for the purpose
18 of evaluating immunologic response to certain anti-
19 gens.”.

20 (b) EFFECTIVE DATE.—

21 (1) IN GENERAL.—Subject to paragraph (2),
22 the amendments made by this section shall apply
23 with respect to items and services provided on or
24 after January 1, 2021.

1 (2) EXCEPTION FOR STATE LEGISLATION.—In
2 the case of a State plan under title XIX of the So-
3 cial Security Act (42 U.S.C. 1396 et seq.) that the
4 Secretary of Health and Human Services determines
5 requires State legislation in order for the respective
6 plan to meet any requirement imposed by amend-
7 ments made by this section, the respective plan shall
8 not be regarded as failing to comply with the re-
9 quirements of such title solely on the basis of its
10 failure to meet such an additional requirement be-
11 fore the first day of the first calendar quarter begin-
12 ning after the close of the first regular session of the
13 State legislature that begins after the date of the en-
14 actment of this Act. For purposes of the previous
15 sentence, in the case of a State that has a 2-year
16 legislative session, each year of the session shall be
17 considered to be a separate regular session of the
18 State legislature.

19 **SEC. 4. MEDICARE COVERAGE FOR ALLERGY DIAGNOSTIC**
20 **TESTING SERVICES.**

21 (a) COVERAGE.—Section 1861 of the Social Security
22 Act (42 U.S.C. 1395x) is amended—

23 (1) in subsection (s)(2)—

24 (A) in subparagraph (GG), by striking
25 “and” at the end;

1 (B) in subparagraph (HH), by striking the
2 period at the end and inserting “; and”; and

3 (C) by adding at the end the following new
4 subparagraph:

5 “(II) allergy diagnostic testing services (as de-
6 fined in subsection (kkk));”; and

7 (2) by adding at the end the following new sub-
8 section:

9 “(kkk) ALLERGY DIAGNOSTIC TESTING SERVICES.—

10 “(1) IN GENERAL.—The term ‘allergy diag-
11 nostic testing services’ means in vitro specific IgE
12 tests and percutaneous tests—

13 “(A) that have been cleared under section
14 501(k), classified under section 513(f)(2), or
15 approved under section 515 of the Federal
16 Food, Drug, and Cosmetic Act; and

17 “(B) which are furnished to individuals for
18 the purpose of evaluating immunologic response
19 to certain antigens, as determined appropriate
20 by the practitioner ordering such test.

21 “(2) EQUAL ACCESS TO TESTING METHODS.—

22 The Secretary shall ensure equality in the treatment
23 of in vitro specific IgE tests and percutaneous tests
24 described in paragraph (1) with respect to—

1 “(A) any medical necessity or other cov-
2 erage requirements established for such in vitro
3 specific IgE and percutaneous tests;

4 “(B) any frequency limits established for
5 such tests; and

6 “(C) any allergen unit limits established
7 for a year for such tests.”.

8 (b) PAYMENT.—Section 1834 of the Social Security
9 Act (42 U.S.C. 1395m) is amended by adding at the end
10 the following new subsection:

11 “(x) ALLERGY DIAGNOSTIC TESTING SERVICES.—
12 For purposes of payment only, in the case of allergy diag-
13 nostic testing services (as defined in section 1861(kkk))—

14 “(1) in vitro specific IgE tests shall be treated
15 as clinical diagnostic laboratory tests; and

16 “(2) percutaneous tests shall be treated as phy-
17 sicians’ services.”.

18 (c) EFFECTIVE DATE.—The amendments made by
19 this section shall apply with respect to items and services
20 furnished on or after January 1, 2021.